Is this you? Create Your Porfile

Mark Levis

St. Jude Children's Research Hospital

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Mark Levis is active.

Explore More

Publication

Featured researches published by Mark Levis.

Archive | 2014

Treatment With Quizartinib (AC220) Enables a High Rate of Patients With Relapsed or Refractory FLT3-ITD(+) Acute Myeloid Leukemia to be Bridged to HSCT

Giovanni Martinelli; Mark Levis; Alexander E. Perl; Hervé Dombret; Björn Steffen; Philippe Rousselot; Elihu H. Estey; Neil P. Shah; Guy Gammon; Denise Trone; Jorge Cortes; Aml Progression

Blood | 2004

FLT3-Targeted Therapy Selectively Kills MLL-Rearranged Infant and Childhood ALL Blasts In Vitro and in Vivo.

Patrick O. Brown; Obdulio Piloto; Mark Levis; Sheila A. Shurtleff; Dario Campana; James R. Downing; Donald Small

Archive | 2014

myeloid leukemia cells in acute - CD38 + A clinically relevant population of leukemic CD34

Saul J. Sharkis; Michael J. Borowitz; Judith E. Karp; Steven Galkin; Michael I. Collector; Brandy Perkins; Mark Levis; Constance A. Griffin; Jonathan M. Gerber; B. Douglas Smith; Hao Zhang; Milada S. Vala

Archive | 2013

insights into the basis for cytotoxic response to FLT3 inhibitors Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals

Johannes Roesel; Judith E. Karp; Ilene Galinsky; Frank Giles; Elihu H. Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Mark Levis; Patrick O. Brown; B. Douglas Smith; Adam Stine; Rosalyn Pham

Archive | 2013

cyclophosphamide for adults with refractory acute leukemias A phase 1 clinical-laboratory study of clofarabine followed by

B. Douglas Smith; Michael A. McDevitt; Hetty E. Carraway; Mark Levis; Varsha Gandhi; Judith E. Karp; Rebecca M. Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer

Archive | 2013

leukemia clinical activity in patients with relapsed or refractory acute myeloid

Mark Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small; B. Douglas Smith; Mark Levis; Miloslav Beran; Francis J. Giles; Hagop Kantarjian; Karin D. Berg

Archive | 2013

fit for intensive chemotherapy treatment for older patients with acute myeloid leukemia not considered A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line

Richard E. Clark; Mark Levis; Donald Small; Steven Knapper; Alan K. Burnett; Tim Littlewood; W. Jonathan Kell; Sam Agrawal; Raj Chopra

Archive | 2012

followed by cytosine arabinoside and mitoxantrone for acute leukemias Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol

Michelle A. Rudek; Michael A. McDevitt; Karen Mackey; Janet Briel; L. Austin Doyle; Katrina Alino; Mark Levis; Steven D. Gore; Biju Joseph; E. Karp; B. Douglas Smith; Linda S. Resar; Jacqueline Greer; Amanda Blackford

Archive | 2010